Showing results (261-270 of 928) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|December 2, 2022
Treating chronic diseases without tackling excess adiposity promotes multimorbidityNaveed Sattar, John J V McMurray, Iain B McInnes, et al.
The Lancet. Diabetes & Endocrinology|June 20, 2022
Type 1 diabetes in diverse ancestries and the use of genetic risk scoresMaria J Redondo, Christopher R Gignoux, Dana Dabelea, et al.
The Lancet. Diabetes & Endocrinology|May 27, 2019
Diabetes in pregnancy and epigenetic mechanisms-how the first 9 months from conception might affect the child's epigenome and later risk of diseaseLine Hjort, Boris Novakovic, Louise G Grunnet, et al.
The Lancet. Diabetes & Endocrinology|July 15, 2019
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statementIan J Neeland, Robert Ross, Jean-Pierre Després, et al.
The Lancet. Diabetes & Endocrinology|August 29, 2014
Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic reviewStefan L C Geijselaers, Simone J S Sep, Coen D A Stehouwer, et al.
The Lancet. Diabetes & Endocrinology|September 18, 2015
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study
The Lancet. Diabetes & Endocrinology|May 18, 2016
Phenotypes of prediabetes and stratification of cardiometabolic riskNorbert Stefan, Andreas Fritsche, Fritz Schick, et al.
The Lancet. Diabetes & Endocrinology|August 8, 2017
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysisKåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, et al.
The Lancet. Diabetes & Endocrinology|September 18, 2017
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trialRury R Holman, Ruth L Coleman, Juliana C N Chan, et al.
The Lancet. Diabetes & Endocrinology|September 19, 2017
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trialParesh Dandona, Chantal Mathieu, Moshe Phillip, et al.
Pageof 93